Header

UZH-Logo

Maintenance Infos

Validation of the Global Allergy and Asthma European Network (GA(2)LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber - Zurich Open Repository and Archive


Zuberbier, Torsten; Abelson, Mark B; Akdis, Cezmi A; Bachert, Claus; Berger, Uwe; Bindslev-Jensen, Carsten; Boelke, Georg; Bousquet, Jean; Canonica, Giorgio Walter; Casale, Thomas B; Jutel, Marek; Kowalski, Marek L; Madonini, Enzo; Papadopoulos, Nikolaos G; Pfaar, Oliver; Sehlinger, Torsten; Bergmann, Karl-Christian; Global Allergy and Asthma European Network (GA(2)LEN) European U, ? (2017). Validation of the Global Allergy and Asthma European Network (GA(2)LEN) chamber for trials in allergy: Innovation of a mobile allergen exposure chamber. Journal of Allergy and Clinical Immunology, 139(4):1158-1166.

Abstract

BACKGROUND: Field clinical trials of pollen allergy are affected by the impossibility of predicting and determining individual allergen exposure because of many factors (eg, pollen season, atmospheric variations, pollutants, and lifestyles). Environmental exposure chambers, delivering a fixed amount of allergen in a controlled environmental setting, can overcome these limitations. Environmental exposure chambers are currently already used in phase 2, 3, and even 4 trials. Unfortunately, few chambers exist in the world, and this makes it difficult to perform large, multicenter clinical trials. The new Global Allergy and Asthma European Network (GA(2)LEN) mobile exposure chamber is a step forward because the mobility of the chamber makes it convenient for patients to participate in clinical testing.
OBJECTIVE: This study was made to validate the reproducibility, sensitivity, and specificity of the results obtained in the new GA(2)LEN chamber.
METHODS: Seventy-two adult patients (19-61 years old) with allergic rhinitis with or without asthma caused by grass pollen were included in different clinical validation tests. Total symptom scores and total nasal symptom scores were recorded at time zero (0) and every 10 minutes during exposures, along with nasal and respiratory parameters.
RESULTS: Exposure tests confirmed the reproducibility between subsequent runs and the sensitivity (P < .00001 vs patients exposed to placebo) and specificity (very low score in nonallergic subjects) in the GA(2)LEN chamber. No adverse reactions were recorded during the tests.
CONCLUSIONS: The mobility of the GA(2)LEN chamber provides a new, potentially effective, and safe way of generating reliable data in allergy multicenter clinical trials.

Abstract

BACKGROUND: Field clinical trials of pollen allergy are affected by the impossibility of predicting and determining individual allergen exposure because of many factors (eg, pollen season, atmospheric variations, pollutants, and lifestyles). Environmental exposure chambers, delivering a fixed amount of allergen in a controlled environmental setting, can overcome these limitations. Environmental exposure chambers are currently already used in phase 2, 3, and even 4 trials. Unfortunately, few chambers exist in the world, and this makes it difficult to perform large, multicenter clinical trials. The new Global Allergy and Asthma European Network (GA(2)LEN) mobile exposure chamber is a step forward because the mobility of the chamber makes it convenient for patients to participate in clinical testing.
OBJECTIVE: This study was made to validate the reproducibility, sensitivity, and specificity of the results obtained in the new GA(2)LEN chamber.
METHODS: Seventy-two adult patients (19-61 years old) with allergic rhinitis with or without asthma caused by grass pollen were included in different clinical validation tests. Total symptom scores and total nasal symptom scores were recorded at time zero (0) and every 10 minutes during exposures, along with nasal and respiratory parameters.
RESULTS: Exposure tests confirmed the reproducibility between subsequent runs and the sensitivity (P < .00001 vs patients exposed to placebo) and specificity (very low score in nonallergic subjects) in the GA(2)LEN chamber. No adverse reactions were recorded during the tests.
CONCLUSIONS: The mobility of the GA(2)LEN chamber provides a new, potentially effective, and safe way of generating reliable data in allergy multicenter clinical trials.

Altmetrics

Downloads

15 downloads since deposited on 05 Jan 2017
15 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Swiss Institute of Allergy and Asthma Research
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2017
Deposited On:05 Jan 2017 10:15
Last Modified:06 Apr 2017 01:02
Publisher:Elsevier
ISSN:0091-6749
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1016/j.jaci.2016.08.025
PubMed ID:27697498

Download

Preview Icon on Download
Preview
Content: Published Version
Filetype: PDF
Size: 1MB
View at publisher
Licence: Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

TrendTerms

TrendTerms displays relevant terms of the abstract of this publication and related documents on a map. The terms and their relations were extracted from ZORA using word statistics. Their timelines are taken from ZORA as well. The bubble size of a term is proportional to the number of documents where the term occurs. Red, orange, yellow and green colors are used for terms that occur in the current document; red indicates high interlinkedness of a term with other terms, orange, yellow and green decreasing interlinkedness. Blue is used for terms that have a relation with the terms in this document, but occur in other documents.
You can navigate and zoom the map. Mouse-hovering a term displays its timeline, clicking it yields the associated documents.

Author Collaborations